Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 2691

1.

The relationship between HER2 overexpression and angiogenesis in gastric cancer.

Ciesielski M, Szajewski M, Pęksa R, Lewandowska MA, Zieliński J, Walczak J, Szefel J, Kruszewski WJ.

Medicine (Baltimore). 2018 Oct;97(42):e12854. doi: 10.1097/MD.0000000000012854.

2.

Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer.

Woestemeier A, Ghadban T, Riethdorf S, Harms-Effenberger K, Konczalla L, Uzunoglu FG, Izbicki JR, Pantel K, Bockhorn M, Reeh M.

Anticancer Res. 2018 Oct;38(10):5665-5669. doi: 10.21873/anticanres.12902.

PMID:
30275185
3.

Variability in HER2 expression between primary colorectal cancer and corresponding metastases.

Shan L, Lv Y, Bai B, Huang X, Zhu H.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2275-2281. doi: 10.1007/s00432-018-2744-z. Epub 2018 Sep 10.

PMID:
30203148
4.

Breast cancer in a tertiary cancer center in India - An audit, with outcome analysis.

Nair N, Shet T, Parmar V, Havaldar R, Gupta S, Budrukkar A, Sarin R, Thakur M, Desai S, Yadav P, Jalali R, Gulia S, Wadasadawala T, Gosh J, Bajpai J, Kembhavi S, Patil A, Joshi S, Popat P, Rangarajan V, Shah S, Vanmali V, Siddiqui S, Mittra I, Badwe R.

Indian J Cancer. 2018 Jan-Mar;55(1):16-22. doi: 10.4103/ijc.IJC_484_17.

5.

Association of HER2 gene amplification and tumor progression in early gastric cancer.

Kanayama K, Imai H, Usugi E, Shiraishi T, Hirokawa YS, Watanabe M.

Virchows Arch. 2018 Nov;473(5):559-565. doi: 10.1007/s00428-018-2433-y. Epub 2018 Aug 17.

PMID:
30120594
6.

Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.

Christgen M, Bartels S, Luft A, Persing S, Henkel D, Lehmann U, Kreipe H.

Virchows Arch. 2018 Nov;473(5):577-582. doi: 10.1007/s00428-018-2414-1. Epub 2018 Aug 9.

PMID:
30094493
8.

HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.

Park JS, Yoon G, Kim HJ, Park SY, Choi GS, Kang MK, Kim JG, Jang JS, Seo AN.

Virchows Arch. 2018 Oct;473(4):413-423. doi: 10.1007/s00428-018-2409-y. Epub 2018 Jul 28.

PMID:
30056472
9.

Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.

Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M.

Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3.

PMID:
29971625
10.

HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran

Feizy A, Karami A, Eghdamzamiri R, Moghimi M, Taheri H, Mousavinasab N.

Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1721-1725.

11.

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.

Hu ZY, Xie N, Tian C, Yang X, Liu L, Li J, Xiao H, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Xiao M, Tang Y, He Q, Chang L, Xia X, Yi X, Liao Q, Ouyang Q.

EBioMedicine. 2018 Jun;32:111-118. doi: 10.1016/j.ebiom.2018.05.015. Epub 2018 May 26.

12.

Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India

Nadaf AS, Rani H, Dinesh US.

Asian Pac J Cancer Prev. 2018 May 26;19(5):1381-1385.

13.

Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients.

Maria AM, El-Shebiney M, El-Saka AM, Zamzam Y.

J Egypt Natl Canc Inst. 2018 Jun;30(2):49-55. doi: 10.1016/j.jnci.2018.05.001. Epub 2018 May 17.

14.

Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease.

Hirai I, Tanese K, Nakamura Y, Otsuka A, Fujisawa Y, Yamamoto Y, Hata H, Fujimura T, Matsushita S, Yoshino K, Kameyama K, Amagai M, Funakoshi T.

Med Oncol. 2018 May 9;35(6):92. doi: 10.1007/s12032-018-1154-z.

PMID:
29744813
15.

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Asano H, Soh J, Tsukuda K, Nagasaka T, Fujiwara T, Toyooka S.

Cancer Sci. 2018 Apr;109(4):1166-1176. doi: 10.1111/cas.13546. Epub 2018 Mar 25.

16.

Ultrasensitive direct impedimetric immunosensor for detection of serum HER2.

Sharma S, Zapatero-Rodríguez J, Saxena R, O'Kennedy R, Srivastava S.

Biosens Bioelectron. 2018 May 30;106:78-85. doi: 10.1016/j.bios.2018.01.056. Epub 2018 Jan 31.

PMID:
29414093
17.

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.

Verma S, Goyal S, Kumari A, Singh A, Jamal S, Grover A.

PLoS One. 2018 Feb 1;13(2):e0190942. doi: 10.1371/journal.pone.0190942. eCollection 2018.

18.

Disposable inkjet-printed electrochemical platform for detection of clinically relevant HER-2 breast cancer biomarker.

Carvajal S, Fera SN, Jones AL, Baldo TA, Mosa IM, Rusling JF, Krause CE.

Biosens Bioelectron. 2018 May 1;104:158-162. doi: 10.1016/j.bios.2018.01.003. Epub 2018 Jan 4.

PMID:
29331430
19.

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Başaran GA, Twelves C, Diéras V, Cortés J, Awada A.

Cancer Treat Rev. 2018 Feb;63:144-155. doi: 10.1016/j.ctrv.2017.12.002. Epub 2017 Dec 6. Review.

PMID:
29329006
20.

ERBB2 mutation: A promising target in non-squamous cervical cancer.

Xiang L, Jiang W, Ye S, He T, Pei X, Li J, Chan DW, Ngan HYS, Li F, Tao P, Shen X, Zhou X, Wu X, Yang G, Yang H.

Gynecol Oncol. 2018 Feb;148(2):311-316. doi: 10.1016/j.ygyno.2017.12.023. Epub 2017 Dec 24.

PMID:
29279289

Supplemental Content

Support Center